7 May 1999
A subsidy of the Swiss multinational pharmaceutical company, Serono Laboratories, is understood to be the front-runner for Bedfont Cross, the 1,810 sq m (19,500 sq ft) Welbeck Land scheme completed at the end of February.
You must be logged in to continue
Register for free to finish this article.
Sign up now for the following benefits:
To access this article REGISTER NOW
Would you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week.